Latest news
Chugai and Debiopharm Group Announce an Exclusive License Agreement for Anti-Cancer Agent, FF284 (Debio 1347)
Dr. Reddy’s launches Debiopharm’s Pamorelin® LA in India for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer
The Japanese Cancer Association and Debiopharm Group™ present Doctors Oshima and Tanaka with the 2012 ‘JCA-Mauvernay Award’ for their innovative…
Debiopharm Group presents the ‘Debiopharm Group Life Sciences Award 2012’ And two ‘Junior Debiopharm Group Life Sciences Awards 2012’ During…
Curis and Debiopharm Announce Initiation of Phase I-II Clinical Study of HSP90 Inhibitor Debio 0932 – Study to test Debio…
Debiopharm Group™ – First patient treated in Phase III study with subcutaneous administration of Debio 8206 for treatment of advanced…
Debiopharm Group is investing in Tweasy, the Saas e-marketing platform for SMEs
Debiopharm, Immunexpress and Biocartis Announce Collaboration to Advance Development of SeptiCyte® Triage for Managing Sepsis